Vaxcyte (PCVX) Current Assets (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Current Assets of $1.8 billion for Q1 2026, up 5.65% year-over-year from $1.7 billion in Q1 2025, and up 11.44% quarter-over-quarter from $1.6 billion in Q4 2025.
Vaxcyte (PCVX) Current Assets (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Current Assets for 8 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 5.65% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 5.65% YoY), while the FY2025 annual figure was $1.6 billion, down 8.98% from the prior year.
- Current Assets advanced to $1.8 billion in Q1 2026 per PCVX's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Current Assets topped out at $2.2 billion in Q3 2024 and bottomed at $342.2 million in Q1 2022.
- Historically, Current Assets has averaged $1.3 billion across 5 years, with a median of $1.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Current Assets surged 267.69% — and 2025, when it slipped 20.18%.
- Vaxcyte's Current Assets stood at $942.6 million in 2022, then rose by 16.27% to $1.1 billion in 2023, then surged by 63.14% to $1.8 billion in 2024, then dropped by 8.98% to $1.6 billion in 2025, then gained by 11.44% to $1.8 billion in 2026.
- Business Quant data shows PCVX's Current Assets at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 1.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.55 Bn |
| Mar 31, 2026 | 1.81 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.77 Bn |
| Jun 30, 2025 | 1.72 Bn |
| Mar 31, 2025 | 1.72 Bn |
| Dec 31, 2024 | 1.79 Bn |
| Sep 30, 2024 | 2.21 Bn |
| Jun 30, 2024 | 1.48 Bn |
| Mar 31, 2024 | 1.52 Bn |
| Dec 31, 2023 | 1.10 Bn |
| Sep 30, 2023 | 1.30 Bn |
| Jun 30, 2023 | 1.31 Bn |
| Mar 31, 2023 | 840.67 Mn |
| Dec 31, 2022 | 942.56 Mn |
| Sep 30, 2022 | 369.76 Mn |
| Jun 30, 2022 | 363.73 Mn |
| Mar 31, 2022 | 342.22 Mn |
| Dec 31, 2021 | 256.35 Mn |
| Sep 30, 2021 | 302.95 Mn |